Autolus Therapeutics Reports 192% Revenue Growth to $26.2 Million, Net Loss of $71.6 Million

Autolus Therapeutics plc reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company generated product revenue of $26.2 million, a substantial increase of 192% compared to $9.0 million in the same period last year. This growth is attributed to the launch of its CAR T-cell therapy, AUCATZYL, in the United Kingdom in January 2026, following its initial launch in the United States in January 2025. Despite the increase in revenue, Autolus reported a net loss of $71.6 million for the quarter, slightly higher than the $70.2 million loss recorded in the prior year.

The company's total operating expenses for the quarter were $85.7 million, up from $74.2 million in the previous year, driven primarily by increased costs in selling, general, and administrative expenses, which rose by 35% to $39.9 million. Research and development expenses decreased by 21% to $21.2 million, reflecting a reduction in clinical trial costs and related support expenses. The increase in operating expenses was partially offset by a decrease in research and development costs, which the company attributes to a shift in its tax credit eligibility under the UK’s R&D tax schemes.

In terms of operational metrics, Autolus reported a cash and cash equivalents balance of $130.9 million and marketable securities of $98.5 million as of March 31, 2026. The company anticipates that these resources will be sufficient to fund its operations for at least the next twelve months. However, it also noted the need for additional capital to support ongoing commercialization efforts and the development of its product pipeline, which includes ongoing clinical trials for its other product candidates.

Strategically, Autolus is undergoing a reduction in workforce, impacting approximately 13% of its employees, as part of a plan to improve operational efficiency and reduce costs. This initiative is expected to save the company approximately $15 million annually starting in 2027. The company has also initiated several clinical trials for its product candidates, including obe-cel for pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia and for lupus nephritis, with data expected to be reported in the coming years.

Looking ahead, Autolus remains focused on expanding the market for AUCATZYL and advancing its clinical programs. The company is actively evaluating opportunities for geographic expansion and potential collaborations to enhance its product offerings. Despite the challenges of operating in the biotechnology sector, including regulatory hurdles and competition, Autolus is positioned to leverage its recent product launches and ongoing clinical trials to drive future growth.